- ISIN
- US0901681058
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Nov 6, 2025
Highlights
- Market Cap
- $5.34B
- Enterprise Value
- $4.95B
- EPS (TTM)
- $0.54
- PE Ratio
- 188.06
- Total Revenue (TTM)
- $354.54M
- Gross Profit (TTM)
- $249.58M
- EBITDA (TTM)
- $41.26M
- Year Range
- $61.96 - $138.70
- Target Price
- $128.67
- ROA (TTM)
- 3.60%
- ROE (TTM)
- 4.99%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BLLN Performance Chart
BillionToOne, Inc (BLLN) is up 23.1% since the beginning of the year. At $101 per share, BLLN is trading 27.4% below its 52-week high of $139.
Loading charts...
Returns By Period
BillionToOne, Inc
- 1D
- -4.21%
- 1M
- 17.23%
- YTD
- 23.07%
- 6M
- 4.60%
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
BLLN Monthly Returns History
Based on dividend-adjusted daily data since Nov 6, 2025, BLLN's average daily return is +0.16%, while the average monthly return is +2.31%. At this rate, an investment would double in approximately 2.5 years.
Historically, 63% of months were positive and 38% were negative. The best month was May 2026 with a return of +31.9%, while the worst month was Dec 2025 at -37.1%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 1 months.
On a daily basis, BLLN closed higher 51% of trading days. The best single day was Jan 12, 2026 with a return of +15.4%, while the worst single day was Feb 23, 2026 at -15.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.82% | -7.49% | 3.42% | -4.93% | 31.90% | 1.75% | 23.07% | ||||||
| 2025 | 30.18% | -37.13% | -18.16% |
Benchmark Metrics
BillionToOne, Inc has an annualized alpha of 13.87%, beta of 1.74, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since November 06, 2025.
- This stock captured 517.24% of S&P 500 Index gains and 379.15% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 13.87%
- Beta
- 1.74
- R²
- 0.07
- Upside Capture
- 517.24%
- Downside Capture
- 379.15%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for BillionToOne, Inc (BLLN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BLLN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | — | 1.37 | — |
| Calmar ratioReturn relative to maximum drawdown | — | 2.78 | — |
| Martin ratioReturn relative to average drawdown | — | 12.44 | — |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the BillionToOne, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BillionToOne, Inc was 50.81%, occurring on Mar 12, 2026. The portfolio has not yet recovered.
The current BillionToOne, Inc drawdown is 22.63%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -50.81%Mar 2026 | 3mo 11d | — | 6mo 24dDec 2025 - now |
2025 correction2025 | -17.80%Nov 2025 | 6d | 8d | 14dNov 2025 - Nov 2025 |
2025 pullback2025 | -1.58%Nov 2025 | 0s | 2d | 2dNov 2025 - Nov 2025 |
Drawdown Indicators
| BLLN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -50.81% | -56.78% | +5.97% |
Max Drawdown (1Y)Largest decline over 1 year | — | -9.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -22.63% | -1.80% | -20.83% |
Average DrawdownAverage peak-to-trough decline | -30.29% | -10.71% | -19.58% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 2.03% | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of BillionToOne, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how BillionToOne, Inc is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for BLLN, comparing it with other companies in the Diagnostics & Research industry. Currently, BLLN has a P/E ratio of 188.1. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BLLN relative to other companies in the Diagnostics & Research industry. Currently, BLLN has a P/S ratio of 13.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BLLN in comparison with other companies in the Diagnostics & Research industry. Currently, BLLN has a P/B value of 10.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BLLN
Add BillionToOne, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BLLN